Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-122377
Filing Date
2024-11-06
Accepted
2024-11-06 16:27:20
Documents
58
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q prld-20240930.htm   iXBRL 10-Q 1696591
2 EX-31.1 prld-ex31_1.htm EX-31.1 16375
3 EX-31.2 prld-ex31_2.htm EX-31.2 16385
4 EX-32.1 prld-ex32_1.htm EX-32.1 8918
5 EX-32.2 prld-ex32_2.htm EX-32.2 9051
  Complete submission text file 0000950170-24-122377.txt   7411677

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT prld-20240930.xsd EX-101.SCH 1085869
60 EXTRACTED XBRL INSTANCE DOCUMENT prld-20240930_htm.xml XML 1358758
Mailing Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805
Business Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805 (302) 467-1280
Prelude Therapeutics Inc (Filer) CIK: 0001678660 (see all company filings)

EIN.: 811384762 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39527 | Film No.: 241431462
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)